(415) 353-7070 (appts)
(415) 353-7692 (fax)

Box 0875, UCSF; San Francisco, CA 94143-0875

additional websites:

UCSF Physician Referral Directory

University of Pennsylvania, Philadelphia, PA, B.A., 1984
Tufts University School of Medicine, Boston, MA, M.D., 1988
The New York Hospital - Cornell Medical Center, New York, NY, 1988-1991, Internal Medicine (Residency)
Memorial Sloan-Kettering Cancer Center, New York, NY, 1991-1996, Medical Oncology (Fellowship)

Moasser MM., DeBlasio A, and Dmitrovsky E. Response and resistance to retinoic acid are mediated through the retinoic acid nuclear receptorγ in human teratocarcinomas. Oncogene 1994; 9: 833-840.

Moasser, MM, Reuter V, Dmitrovsky E. Over-expression of the retinoic acid receptor directly induces terminal differentiation of human embryonal carcinoma cells. Oncogene 1995; 10: 1537-1543.

Ahn MJ, Nason-Burchenal K, Moasser MM, Dmitrovsky E. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RARα or PML. Oncogene 1995; 10: 2307-2314.

Moasser,MM, Motzer RJ, Khoo KS, Lyn P, Murphy B, Bosl GJ, Dmitrovsky E. All-Trans Retinoic Acid for Germ Cell Tumors: In Vitro Activity and Results of a Phase II Study, Cancer 1995; 76: 680-686.

Ahn MJ, Langenfeld J, Moasser MM, Rusch V, and Dmitrovsky E. Growth suppression of transformed human bronchial epithelial cells by all-trans retinoic acid occurs through specific retinoid receptors, Oncogene 1995; 11: 2357-2364.

Baldassarre G, Bianco C, Tortora G, Ruggiero A, Moasser M, Dmitrovsky E, Bianco AR, and Ciardiello F. Transfection with a cripto anti-sense plasmid suppresses endogenous cripto expression and inhibits transformation in a human embryonal carcinoma cell line. Int. J. Cancer 1996; 66: 538-543.

Moasser MM, Khoo KS, Maerz W, Zelenetz A, Dmitrovsky E. Derivation and characterization of retinoid resistant human embryonal carcinoma cells. Differentiation 1996; 60: 251-257.

Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Baalog A, Su D, Danishefsky SJ, and Rosen N. Farnesyl Transferase Inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl. Acad. Sci. USA 1999; 95: 1369-1374.

Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, and Rosen N. Inhibition of src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Research 1999; 54: 6145-6152.

Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI. Farnesyl:protein transferase inhibitors as potential agents for the management of prostate cancer. Prostate Cancer and Prostatic Diseases 2001; 4: 33-43.

Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 (ÔIressaÕ) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumors. Cancer Research 2001; 61: 7184-7188.

Munster PN. Srethapakdi M. Moasser MM. Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells Cancer Research 2001; 61:2945-52.

Moasser MM & Rosen N. Molecular markers in the farnesyltransferase inhibitor (FTI) therapy of breast cancers. Breast Cancer Research & Treatment 2002; 73:135-144.

Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-abl driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clinical Cancer Research 2003; 9: 1267-1273.

She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib (ZD1839, Iressa) in PTEN null HER overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive PI3K/Akt pathway signaling. Clinical Cancer Research 2003; 9: 4340-4346.

Mizenina OA & Moasser MM. S-phase Inhibition of Cell Cycle Progression by a Novel Class of Pyridopyrimidine Tyrosine Kinase Inhibitors. Cell Cycle 3; p796-803 (2004).

Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion Signaling by a novel mitotic substrate of src kinases. Oncogene 24; p5333-5343 (2005).

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3. Nature 445; p437-441 (2007).

Moasser MM, Wilmes LJ, Wong CH, Li K, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Mag Res Imag 2007 26:1618-25.

Moasser MM. The oncogene HER2; Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26; p6469-6487 (2007).

Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26; p6577-6592 (2007).

Hsieh AC & Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97; p453-457 (2007).

Sergina NV & Moasser MM. The HER family: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 13; p527-534 (2007).

7/22/08